[Antiangiogenic effect of continuous low-dose chemotherapy on XXXX ].

@entity137 @entity3525 @entity353 @entity19 @entity5 @entity2 @entity786 @entity1431 @entity1611
BACKGROUND: Recently a number of preclinical studies have sparked interest in the concept of exploiting conventional chemotherapeutic drugs as antiangiogenics. Such antiangiogenic activity is achieved by metronomic-dosing (low-dose) protocols. This new target may have some advantages in avoiding @entity137 and resistance caused by chemotherapeutic drugs. This study is to test the efficacy of continuous low-dose @entity786 ( @entity3525 ) for antiangiogenic effect on @entity2 , and investigate its antitumor effect and @entity137 . METHODS: C57/BL6 @entity19 bearing @entity2 were randomly divided into three groups, receiving low-dose metronomic (LDM) @entity3525 , maximum tolerated dose (MTD) @entity3525 therapy and saline respectively. @entity5 , @entity353 , peripheral white blood cell counts and survival of @entity19 were monitored in each group. At the end of experiment, @entity5 were resected for immunohistochemical staining. Tumor microvascular density (MVD) and @entity1611 ( @entity1611 ) level were detected by immunohistochemical staining. RESULTS: MVD and @entity1611 expression of @entity5 were much lower in the @entity19 received LDM @entity3525 therapy than those in control group and MTD @entity3525 group (P < 0.05). During the experiment, growth delays of @entity5 were found in the @entity19 received LDM @entity3525 therapy, without apparent body @entity353 or @entity1431 , and the survival of @entity19 was remarkably prolonged, compared with @entity19 received MTD @entity3525 therapy (P < 0.05). CONCLUSIONS: The continuous low-dose regimen of @entity3525 can significantly increase the therapeutic activity with decreased @entity137 and @entity2 . It may act as an antiangiogenic and lead to less drug resistance.
